First Manhattan CO Mersana Therapeutics, Inc. Transaction History

First Manhattan CO

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$3.08 - $9.55 $1.75 Million - $5.44 Million	569,594 New	569,594 $1.87 Million
Q4 2021 Feb 14, 2022	SELL	$5.48 - $9.86 $1.2 Million - $2.15 Million	-218,070 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$8.56 - $14.47 $1.87 Million - $3.16 Million	218,070 New	218,070 $2.06 Million

121

116M

233K

457K

Ticker MRSN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,169,296
Market Cap $198M
Description
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also dev...

Get notified when there are updates to the investment portfolio of First Manhattan CO, based on Form 13F filings with the SEC.

Stay updated on First Manhattan CO with notifications on news.